A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases. With extraordinary patient focus, we strive to redefine expectations in rare disease. Our two marketed therapies are Galafold®, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti® + Opfolda®, a novel two-component treatment for adults living with late-onset Pompe disease. Galafold® (also referred to as "migalastat") is approved in over 40 countries around the world, including the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan. Additionally, Galafold® has been granted orphan drug designation in the U.S., E.U., U.K., Japan, and several other countries. Pombiliti® + Opfolda® (also referred to as "cipaglucosidase alfa-atga/miglustat") is approved in the U.S., the E.U., the U.K., Canada, Australia, Switzerland, and Japan.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 634M | 634M | 528M | 399M | 329M | 306M |
| Net Income | -27M | -27M | -56M | -152M | -237M | -250M |
| EPS | $-0.09 | $-0.09 | $-0.18 | $-0.51 | $-0.82 | $-0.92 |
| Free Cash Flow | 30M | 30M | -37M | -77M | -170M | -206M |
| ROIC | -926.0% | 5.2% | 6.4% | -27.7% | -45.9% | -35.9% |
| Gross Margin | 88.5% | 88.5% | 90.0% | 90.7% | 88.3% | 88.7% |
| Debt/Equity | 1.61 | 1.61 | 2.29 | 2.78 | 3.67 | 1.43 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 33M | 33M | 25M | -77M | -212M | -206M |
| Operating Margin | 5.2% | 5.2% | 4.7% | -19.3% | -64.4% | -67.6% |
| ROE | -9.9% | -11.6% | -28.9% | -94.6% | -192.3% | -81.5% |
| Shares Outstanding | 301M | 301M | 312M | 297M | 288M | 272M |
AMICUS THERAPEUTICS, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 89.2%.
AMICUS THERAPEUTICS, INC. (FOLD) has a 5-year average return on invested capital (ROIC) of -19.6%. This is below average and may indicate limited pricing power.
AMICUS THERAPEUTICS, INC. (FOLD) has a market capitalization of $4.4B. It is classified as a mid-cap stock.
AMICUS THERAPEUTICS, INC. (FOLD) does not currently pay a regular dividend.
AMICUS THERAPEUTICS, INC. (FOLD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
AMICUS THERAPEUTICS, INC. (FOLD) reported annual revenue of $634 million in its most recent fiscal year, based on SEC EDGAR filings.
AMICUS THERAPEUTICS, INC. (FOLD) has a net profit margin of -4.3%. The company is currently unprofitable.
AMICUS THERAPEUTICS, INC. (FOLD) generated $30 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
AMICUS THERAPEUTICS, INC. (FOLD) has a debt-to-equity ratio of 1.61. This indicates higher leverage, which may increase financial risk.
AMICUS THERAPEUTICS, INC. (FOLD) reported earnings per share (EPS) of $-0.09 in its most recent fiscal year.
AMICUS THERAPEUTICS, INC. (FOLD) has a return on equity (ROE) of -11.6%. A negative ROE may indicate losses or negative equity.
AMICUS THERAPEUTICS, INC. (FOLD) has a 5-year average gross margin of 89.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for AMICUS THERAPEUTICS, INC. (FOLD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AMICUS THERAPEUTICS, INC. (FOLD) has a book value per share of $0.91, based on its most recent annual SEC filing.